Authors
Latest:
Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung CancerJohn Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.
Latest:
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder CancerJohn Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Latest:
Dr. Yarnold on Hypofractionation in the START TrialsJohn Yarnold, MBBS, from The Institute of Cancer Research in London, discusses results from the START trials that examined hypofractionated radioatherapy for women with early breast cancer.
Latest:
VTE in Cancer Patients: New Guidelines Define Role of AnticoagulantsBlood clots and their complications are a major cause of death in cancer patients, and affect up to 20% of persons with cancer at some point in their treatment.
Latest:
Dr. Rosenberg on Non-Metastatic Muscle Invasive Bladder Cancer GuidelinesJonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the new treatment guidelines for patients with non-metastatic muscle invasive bladder cancer.
Latest:
Dr. Hubbard on the Design of the NRG-GI005 Trial in Colorectal CancerJoleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.
Latest:
Searching Appalachia for Next Great Cancer DrugThe natural products produced by microbes found in the environment have led to major therapeutic breakthroughs for a variety of conditions ranging from infectious disease to cancer.
Latest:
Dr. de Souza on Next Steps for Immunotherapy in Head and Neck CancerJonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.
Latest:
Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian CancerJonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.
Latest:
Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian CancerJonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.
Latest:
AKT1 E17K Mutation Targetable in Various Tumors Through AKT InhibitionA multihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor,
Latest:
Nothing Is Ever Simple with WindowsIn last month's column, I talked about Microsoft's newest desktop operating system, Windows 7, and outlined several reasons why you might want to purchase it when it comes out this year. Windows 7 will include some really cool features-like multi-touch technology and usability improvements-that can benefit medical practitioners and their office staff. Because it is in Microsoft's best interest to make the process of upgrading to Windows 7 simple and straightforward, you would think the software giant would put great effort into streamlining the experience.
Latest:
Code OverloadThe ICD-9 medical coding system we’ve all relied on for decades will soon change.
Latest:
Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCLJonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).
Latest:
Dr. Trent on the Need for Novel Combination Strategies in Metastatic GISTJonathan C. Trent, MD, PhD, discusses the need to develop novel combination strategies for the treatment of patients with metastatic gastrointestinal stromal tumors.
Latest:
Dr Trent on The Current Standard of Care and Existing Unmet Needs for Patients with GISTJonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.
Latest:
TRK Fusion Inhibitors in Clinical PracticeExperts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck CancerJonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung CancerJonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.
Latest:
Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell LymphomaJonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.
Latest:
Dr Rosenberg on Efforts to Enhance Urothelial Cancer TreatmentJonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.
Latest:
Dr. Jonathan Henderson Discusses the Professional Need and Business Model for Men's Health ClinicsJonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.
Latest:
The Possibilities for Solid Tumor Modeling With 3D Printers Are Just BeginningThree-dimensional printers are on the cusp of revolutionizing the way every doctor practices medicine.
Latest:
Dr. Wright on Frontline Considerations in Locally Advanced Bladder CancerJonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.
Latest:
Dr. Ledermann on the Treatment Landscape for Rare Gynecologic CancersJonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the treatment landscape for patients with rare gynecologic cancers.
Latest:
Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian CancerJonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.
Latest:
Dr. Mizrahi on Addition of PARP Inhibitors to Chemotherapy in Mutated Pancreatic CancerJonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.
